Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TSC 204 (Primary)
  • Indications Anal cancer; Cervical cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Acronyms PLEXI-T
  • Sponsors TScan Therapeutics

Most Recent Events

  • 06 May 2025 According to a TScan Therapeutics media release, In the first quarter, company continued to enroll into singleplex dose levels in our PLEXI-T the Company look forward to dosing our first patient with multiplex therapy soon, and to sharing Safety and response data for multiplex TCR-T therapy anticipated by the end of the year.
  • 28 Mar 2025 Planned number of patients changed from 100 to 840.
  • 02 Dec 2024 According to a TScan Therapeutics media release, the Company will provide an update on its Phase 1 solid tumor trial during the virtual event will take place on Tuesday, December 10, at 8:00 a.m. ET.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top